Glycoprotein IIb/IIIa inhibitors are a new class of very powerful antiplatelet agents that act by inhibiting fibrinogen interplatelet bridges. Abciximab, tirofiban, lamifiban, and integrelin, all intravenous formulations, have been evaluated in phase II and phase III clinical trials. Although there seem to be relevant differences among drugs, their efficacy in treating acute ischemic syndromes and preventing acute complications of coronary angioplasty has been demonstrated. The major side effect has been an increase in bleeding complications. Future studies will be aimed at optimizing results and improving safety through more accurate assessment of optimal dosage and duration of infusion.
|Translated title of the contribution||Clinical usefulness of glycoprotein IIb/IIIa inhibitors|
|Number of pages||6|
|Journal||Annali Italiani di Medicina Interna|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Internal Medicine